Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | KMO | O15229 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650365 | 0.80 | DYRK1A (0.36) | DYRK1AGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL22650356 | 0.78 | SCN5A (0.39) | SCN5ASMN1; SMN2JAK2 | |
| SCHEMBL8515064 | 0.70 | RARB (0.43) | AAK1KMOSMN1; SMN2LMNAMAPT | |
| SCHEMBL25530905 | 0.70 | SCN5A (0.38) | SCN5ATGFBR1 | |
| SCHEMBL21016920 | 0.69 | ERCC1 (0.49) | KMOIRAK4 | |
| SCHEMBL29520282 | 0.69 | ERCC1 (0.49) | KMOIRAK4 | |
| SCHEMBL18352906 | 0.69 | SCN5A (0.38) | SCN5A | |
| SCHEMBL21849289 | 0.69 | EPHB3 (0.40) | SCN5ASMN1; SMN2LMNAPOLBMAPT | |
| SCHEMBL28647094 | 0.68 | MAPT (0.40) | GABRA1GABRG2GABRB3GABRA3AAK1 | |
| SCHEMBL29491179 | 0.68 | SCN5A (0.38) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | SCN5A 3231/4885DYRK1A 691/4885GABRA1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.